PARTNER NEWS:Thu, Apr 18, 6:51 AM, Zacks
Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.
Mon, Apr 15, 4:20 AM, Zacks
Should You Invest in the VanEck Biotech ETF (BBH)?
Sector ETF report for BBH